👩⚕️ One of the biggest challenges in oncology is resistance. 1 in 2 people will be diagnosed with cancer in their lifetime, and over 90 % of cancer deaths are caused by drug resistance, one of the biggest unmet medical needs in the field of cancer. 👨⚕️ 🎯 At Heidelberg Pharma AG the patient is the focus of all our efforts! Our amanitin-based ADC pipeline is designed to overcome resistance. 🎯 📌 Learn more about our patient-focused approach by watching our R&D webinar: https://lnkd.in/eVJygzyn #ADCs #ATAC #CancerResearch
Heidelberg Pharma AG
Biotechnologieforschung
Ladenburg, Baden-Württemberg 4.736 Follower:innen
Making the compound Amanitin available for cancer therapies
Info
Heidelberg Pharma AG based in Ladenburg, Germany, is a biopharmaceutical company listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard. Heidelberg Pharma is focused on oncology and is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary platform is being applied to develop the Company’s own therapeutic ATACs and third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. Former clinical assets MESUPRON® and REDECTANE® have been partnered. Our mission is to research and develop therapies for cancer patients enabling them to receive a targeted and tailor-made course of treatment that is both highly effective and as well-tolerated as possible.
- Website
-
http://www.heidelberg-pharma.com
Externer Link zu Heidelberg Pharma AG
- Branche
- Biotechnologieforschung
- Größe
- 51–200 Beschäftigte
- Hauptsitz
- Ladenburg, Baden-Württemberg
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 1997
- Spezialgebiete
- Onkologie, ADC, ATAC und Amanitin
Orte
-
Primär
Gregor-Mendel-Straße 22
Ladenburg, Baden-Württemberg 68526, DE
Beschäftigte von Heidelberg Pharma AG
Updates
-
🔬 Discover the future of #cancertherapy with our innovative ATACs! 🔬 "Our payload is different...we truly believe that the long-term response is improved with the application of ATACs into cancer therapy with a mechanism of cytotoxicity which is radically different from conventional chemotherapy." Watch the full webinar to learn more from Heidelberg Pharma AG CEO, Andreas Pahl about how we're revolutionizing cancer treatment, alongside Key Opinion Leaders in the ADC field, Jonathan Kaufman and Rakesh Dixit, Ph.D., DABT: 📌 https://lnkd.in/eVJygzyn #ADCs #ATAC #CancerResearch
-
📢 Our colleagues Andras Strassz, MD, MBA, Michael Kulke and Kristin Decker are attending the ADC Toxicity Summit. We are looking forward to many great talks and inspiring discussions! See you tomorrow in Boston! 📢 #HeidelbergPharma #ADC #ATAC #CancerReserach
-
🏃♂️ LAUFend gegen Krebs – das Team von Heidelberg Pharma AG hat ein weiteres Zeichen für eine Welt gegen Krebs gesetzt. 🏃♀️ Beim diesjährigen NCT-Lauf des National Center for Tumor Diseases (NCT) Heidelberg waren wir mit am Start und haben gemeinsam mehrere hundert Kilometer für die gute Sache zurückgelegt. Ein Einsatz ihrer Mitarbeiterinnen und Mitarbeiter, den die Heidelberg Pharma AG gerne mit einer Spende pro zurückgelegtem Kilometer belohnt. 📢 Erfahren Sie mehr über die Heidelberg Pharma AG, ihre einzigartigen #ADC-Technologien und den auf Amanitin-basierenden klinischen Hauptkandidaten HDP-101unter https://lnkd.in/eUnFbuU7 📢
-
Heidelberg Pharma AG is proud to be featured in Clarivate's Companies to Watch report, highlighting the most exciting companies in the ADC space right now. To learn more about our innovative approach to #ADCs using #amanitin-based compounds as the payload, read the full report at the link below. #HeidelbergPharma
Heidelberg Pharma AG, first in the world to develop amanitin for cancer therapy, is one of the seven innovative companies listed in the Clarivate Companies to Watch report this year. Heidelberg Pharma AG uses its proprietary ADC payload (ATAC® technology) to develop ADCs called ATACs that have amanitin-based compounds as the payload. Why is Heidelberg Pharma AG a company to watch? Download the report to discover innovations transforming drug discovery and development, revolutionizing cancer treatment, and capturing big pharma interest, here: https://lnkd.in/eCSaAWtu #oncology #cancertreatement #biotech #pharma #companiestowatch
-
📣Heidelberg Pharma AG announces report on the first half-year 2024 📣 Highlights included: 🎯 First preliminary efficacy data from the clinical trial with HDP-101 in multiple myeloma published 🎯 Presentation of preclinical and clinical data of the proprietary ADC technology platforms at the AACR Meeting 2024 🎯 HDP-101 granted Orphan Drug Designation by the FDA 🎯 Sale of a portion of future royalties for TLX250-CDx to HealthCare Royalty 🎯 Professor Andreas Pahl takes over as Chief Executive Officer 📌 Press release: https://t1p.de/4rbzc 📌 Half-year financial report 2024: https://t1p.de/9edqp
-
📽 Hear from our CEO, Andreas Pahl, on the groundbreaking potential of our amanitin based ADC candidates: "We can overcome resistance – we have never found any tumour cell which was resistant to the amanitin mode-of-action.” 📽 For more insights into our unique approach, including expert perspectives from Key Opinion Leaders, Jonathan Kaufman and Rakesh Dixit, Ph.D., DABT, watch our full R&D webinar here: https://lnkd.in/eVJygzyn #ADCs #ATAC #CancerResearch
-
🎥 Missed Our R&D Webinar - Developing novel ADC drugs for target and highly effective cancer treatment? Catch Up Now! 🎥 Discover how Heidelberg Pharma AG is pushing the boundaries in ADC development and listen📢 to our CEO, Andreas Pahl, share his key insights on our mission and strategy. "That’s the mission of our company – we want to create value through the development of best-in-class ADCs.” Watch the full webinar here https://lnkd.in/eVJygzyn, featuring presentations from our management team, alongside Key Opinion Leaders in the ADC field, Jonathan Kaufman and Rakesh Dixit, Ph.D., DABT. #ADCs #ATAC #CancerResearch
-
In April, the Heidelberg Pharma AG team attended AACR in San Diego, where we presented promising first efficacy data on our lead clinical #ATAC product candidate, HDP-101, targeting relapsed and refractory multiple myeloma. Our CMO, Andras Strassz, MD, MBA, spoke to Drug Discovery World´s Megan Thomas about his key takeaways from the conference and our goal of making #Amanitin available as a cancer therapy. Check out Drug Discovery World's latest issue, linked here: https://lnkd.in/gtSZijU9 #ADCs #ATAC #ACR24 #CancerResearch
-
Our lead candidate, #HDP-101, is the first #amanitin-based #ADC in clinical development and currently demonstrating promising initial first in human results in relapsed and refractory multiple myeloma in a Phase 1/2a study. Read the below insight from Optimum Strategic Communications to find out more about our unique #ATAC technology and how #HeidelbergPharma is harnessing the destructive power of alpha-Amanitin to attack cancer cells.
The death cap mushroom is feared throughout the world because of the deadly toxin it contains, amanitin. But our client Heidelberg Pharma AG thinks amanitin could be used to fight cancer - find out more in our latest feature. #cancer #pharma #mushrooms
Death cap poison: the latest weapon in the fight against cancer
Optimum Strategic Communications auf LinkedIn